InMode Ltd. Form 6-K Summary
Business Context and Reporting Period
InMode Ltd., an Israeli foreign private issuer, filed this Form 6-K for April 2021 on April 26, 2021. The filing reports entry into a material definitive agreement dated April 23, 2021.
Material Transaction
InMode entered into a share exchange agreement with Dilazar Limited, Wigmore Medical Limited, and Invasix UK Limited, the UK joint venture. Dilazar agreed to sell InMode all of its outstanding shares in the UK joint venture, representing 49% of the joint venture immediately before the transaction. Wigmore agreed to sell InMode all of its rights under the Founders Memorandum of Understanding dated March 4, 2014.
In consideration, InMode will issue Dilazar 228,956 ordinary shares in a private placement. The transaction is subject to customary closing conditions and is expected to close by June 30, 2021, provided those conditions are satisfied.
Financial Metrics and Liquidity
The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, guidance, or other operating financial metrics.
Outlook, Risks, and Unusual Items
- Completion is conditional and is not guaranteed until customary closing conditions are satisfied.
- The transaction will result in the issuance of additional ordinary shares, creating potential dilution for existing shareholders.
- The filing does not describe the purchase accounting, valuation, strategic rationale, expected financial impact, or other material terms beyond the share exchange.
Key Facts for Investors to Verify
- Whether the transaction closed by June 30, 2021.
- The final ownership structure of the UK joint venture following closing.
- The number of InMode shares outstanding after issuance of the 228,956 shares.
- Any subsequent disclosure regarding the transaction’s accounting treatment, valuation, or impact on results.
- The complete terms and conditions in Exhibit 10.1, the Share Exchange Agreement dated April 23, 2021.